文献速递MDS 与骨髓增殖性肿瘤白血病

接受低甲基化药物治疗的高危MDS和AML患者侵袭性真菌感染的风险

Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
PubMed 文献 · Am J Hematol · 2020-05-04

这项回顾性研究在大型美国综合癌症中心纳入203例接受至少两个周期低甲基化药物(HMA)治疗的AML、中危至极高危MDS或慢性粒单核细胞白血病患者,采用EORTC/IFICG标准定义侵袭性真菌感染(IFI),IFI发生率为9.6%,其中20例在HMA后诊断(3例确诊、4例很可能、13例可能),确诊病原体包括足放线病菌属和镰刀菌属,11例在启动HMA时中性粒细胞减少,多数感染(17/20)发生于前四个周期。作者认为,鉴于该发生率,对治疗开始时中性粒细胞减少的患者可考虑覆盖霉菌的预防。

要点

  • 203例接受至少两个周期HMA治疗的AML/MDS/CMML患者中,IFI发生率为9.6%。
  • 20例IFI中3例确诊、4例很可能、13例可能;确诊霉菌包括足放线病菌属和镰刀菌属。
  • 11例发生IFI的患者在启动HMA时中性粒细胞减少,17/20例感染发生于前四个周期。

核心结论

  • 接受HMA治疗的高危MDS/AML患者IFI发生率为9.6%,作者认为对治疗开始时中性粒细胞减少的患者可考虑覆盖霉菌的预防。

研究设计与样本

  • 回顾性研究,在大型美国综合癌症中心纳入203例接受至少两个周期HMA治疗的AML、中危至极高危MDS或慢性粒单核细胞白血病患者。
  • IFI按欧洲癌症研究与治疗组织/侵袭性真菌感染协作组(EORTC/IFICG)标准定义。

主要发现

  • IFI发生率为9.6%,20例在HMA后诊断,其中3例确诊、4例很可能、13例可能。
  • 确诊IFI的霉菌包括足放线病菌属(Scedosporium)和镰刀菌属(Fusarium)。
  • 11例发生IFI的患者在启动HMA时中性粒细胞减少。
  • 多数感染(17/20)发生于前四个周期。

关键数值与推荐

  • IFI定义采用EORTC/IFICG标准。
  • IFI发生率为9.6%(20/203)。
  • 20例IFI中3例确诊、4例很可能、13例可能。

临床怎么用

  • 作者认为,鉴于该发生率,对治疗开始时中性粒细胞减少的患者可考虑覆盖霉菌的预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Invasive fungal infections (IFI) are a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Given the heterogeneity of the population receiving hypomethylating agents (HMA), it is difficult for clinicians to accurately assess their patients' risk of infection. Literature on the incidence of IFI following HMA is limited to several studies of azacitidine. The primary objective of this retrospective study was to establish the incidence of IFI in HMA treated AML/MDS patients at a large U.S. comprehensive cancer center. Secondary objectives included comparing incidence of IFI among pre-specified subgroups to identify potential risk factors for IFI. Two hundred three patients with AML, intermediate to very high risk MDS or chronic myelomonocytic leukemia who received at least two cycles of HMA were included. The incidence of IFI, as defined by the European Organization for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group criteria, was 9.6%, with 20 IFI diagnosed following HMA (three proven, four probable, 13 possible). Among the proven cases of IFI, molds included Scedosporium and Fusarium spp. Eleven patients who developed IFIs were neutropenic upon initiating HMA. The majority (17/20) of infections occurred during the first four cycles. Given this incidence, mold-active prophylaxis can be considered in patients who are neutropenic at the start of therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kim GYG, Burns J, Freyer CW, et al. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. Am J Hematol. 2020. PMID: 32242967. doi:10.1002/ajh.25808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。